Whanganui Chronicle
  • Whanganui Chronicle home
  • Latest news
  • Sport
  • Business
  • Opinion
  • Lifestyle
  • Property
  • Death notices
  • Classifieds

Subscriptions

  • Herald Premium
  • Viva Premium
  • The Listener
  • BusinessDesk

Sections

  • Latest news
  • On The Up
  • Sport
  • Business
  • Opinion
  • Lifestyle
  • Property
    • All Property
    • Residential property listings
  • Rural
    • All Rural
    • Dairy farming
    • Sheep & beef farming
    • Horticulture
    • Animal health
    • Rural business
    • Rural life
    • Rural technology

Locations

  • Taranaki
  • National Park
  • Whakapapa
  • Ohakune
  • Raetihi
  • Taihape
  • Marton
  • Feilding
  • Palmerston North

Media

  • Video
  • Photo galleries
  • Today's Paper - E-Editions
  • Photo sales
  • Classifieds

Weather

  • New Plymouth
  • Whanganui
  • Palmertson North
  • Levin

NZME Network

  • Advertise with NZME
  • OneRoof
  • Driven Car Guide
  • BusinessDesk
  • Newstalk ZB
  • Sunlive
  • ZM
  • The Hits
  • Coast
  • Radio Hauraki
  • The Alternative Commentary Collective
  • Gold
  • Flava
  • iHeart Radio
  • Hokonui
  • Radio Wanaka
  • iHeartCountry New Zealand
  • Restaurant Hub
  • NZME Events

SubscribeSign In

Advertisement
Advertise with NZME.
Home / Whanganui Chronicle

Cystic fibrosis drug Trikafta to add decades to Whanganui local’s life

Emma Bernard
By Emma Bernard
Multimedia journalist·Whanganui Chronicle·
11 Dec, 2022 06:02 PM4 mins to read

Subscribe to listen

Access to Herald Premium articles require a Premium subscription. Subscribe now to listen.
Already a subscriber?  Sign in here

Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech.
‌
Save

    Share this article

Lockie Jones was diagnosed at birth with cystic fibrosis and is eligible for the newly funded life-extending drug Trikafta.

Lockie Jones was diagnosed at birth with cystic fibrosis and is eligible for the newly funded life-extending drug Trikafta.

A Whanganui family is “ecstatic” about the recent funding announcement of a life-changing drug for people with cystic fibrosis.

Lockie Jones, 22, has had cystic fibrosis since birth and is eligible for the recently-funded drug Trikafta.

Pharmac has reached an agreement with medicine supplier Vertex to fund Trikafta in New Zealand, a life-extending drug for those with cystic fibrosis.

Specialists believe the average life expectancy of a person with cystic fibrosis is mid-to-late 30s.

In August 2022, Pharmac acknowledged Trikafta could give people with cystic fibrosis benefits equivalent to 27 more years of full health when compared to current supportive treatments, with data reinforcing that Trikafta reduces the risk of hospitalisations, lung transplants, and premature death.

Advertisement
Advertise with NZME.
Advertisement
Advertise with NZME.

Lockie’s dad Frazer Jones said they were absolutely ecstatic about the news.

“For a young guy, he’s had a lot of stuff thrown at him.”

He said his wife Anna Scoullar-Jones also would have been elated by the news.

Advertisement
Advertise with NZME.

“She passed away four years ago quite suddenly so that was something we also had to deal with.”

Jones said his wife was a huge advocate for people with cystic fibrosis, and the chair of the Central Districts branch of Cystic Fibrosis New Zealand (CFNZ).

“Anna fought for this for a long time and was incredibly proactive. This is what she fought for,” he said.

“Lochie was born with CF, and when he wasn’t feeding properly for 12 hours they shipped us off to Wellington and after they ran some tests that’s when our journey began.”

Jones said managing the condition was quite the regime.

“There are many hospital visits and antibiotics courses, sometimes involving two weeks of IV antibiotics where he has to stay in a hospital room for two weeks at a time.”

He said Lochie, now 22, had strong lung functions compared to many others with cystic fibrosis.

“We know the rollout [of Trikafta] is in April but we’re not quite sure what it all entails yet.”

CFNZ Central North Island community support lead Beverley Darlow said the drug meant decades more good health for Lochie.

“It’ll improve his lung function, digestive system and quality of life,” she said.

Advertisement
Advertise with NZME.

Darlow said the funding news had been a long time coming.

“Many families have tried really hard to get funding for Trikafta and have been rejected, so this is amazing news,” Darlow said.

“I’m a social worker, so you’re usually dealing with the sadder aspects of things and for now things are a lot more positive.

“Now I can support more people to get jobs and to study, so we have many more things to focus on other than just getting through the next hospital visit.”

She said she works with over 100 families through her work.

“Now many of them can look forward to the future.”

Advertisement
Advertise with NZME.

Darlow said in the past she had worked with families who moved overseas to places where Trikafta was already funded.

“Especially to Australia, but there’s still a waiting game for them.”

CFNZ has been advocating for public funding of Trikafta for two and a half years, CFNZ chief executive Lisa Burns said.

“There just aren’t the words to convey what this means for our community,” Burns said.

“Funding Trikafta will bring life-changing benefits to people with CF, their families, whānau, the wider community, and our health system,” Burns said.

She said New Zealand was joining over 30 other countries where Trikafta was funded.

Advertisement
Advertise with NZME.

“Our community no longer need to leave Aotearoa to access this medicine, and those who have already left can now come home to be with their families and whānau.”

Burns said the news would be overwhelming and would take time for the reality to sink in about what it means for people with cystic fibrosis and their families, and the additional years they will now have ahead of them.

“Trikafta should now be the trailblazer to show how modern medicines like this can be funded in New Zealand. We cannot forget those who are still desperately waiting for life-saving medicines,” she said.

“We need to urgently work towards a framework that delivers a fair and equitable system where funding medicines is seen as an investment rather than a cost.

“CFNZ and our CF community have held on tight to the hope that one day this would happen and now we have the Christmas miracle we hoped for.”

Cystic fibrosis is an ultimately terminal condition that affects about 540 people in New Zealand in which the glands that produce mucus, sweat and intestinal secretions do not function properly.

Advertisement
Advertise with NZME.

The condition causes thick mucus to accumulate in the lungs, leading to breathing difficulties and infections.

Trikafta is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator that helps defective CFTR proteins work more effectively.

Save

    Share this article

Latest from Whanganui Chronicle

Whanganui Chronicle

Body of missing man found

Whanganui Chronicle

End of the line for former St George's School buildings

Whanganui Chronicle

Netball: Kaierau edge Pirates in thrilling Premier 1 clash


Sponsored

Solar bat monitors uncover secrets of Auckland’s night sky

Advertisement
Advertise with NZME.

Latest from Whanganui Chronicle

Body of missing man found
Whanganui Chronicle

Body of missing man found

Kahu Gill's body was recovered near the Cobham Bridge on July 14.

16 Jul 08:34 PM
End of the line for former St George's School buildings
Whanganui Chronicle

End of the line for former St George's School buildings

16 Jul 06:00 PM
Netball: Kaierau edge Pirates in thrilling Premier 1 clash
Whanganui Chronicle

Netball: Kaierau edge Pirates in thrilling Premier 1 clash

16 Jul 05:00 PM


Solar bat monitors uncover secrets of Auckland’s night sky
Sponsored

Solar bat monitors uncover secrets of Auckland’s night sky

06 Jul 09:47 PM
NZ Herald
  • About NZ Herald
  • Meet the journalists
  • Newsletters
  • Classifieds
  • Help & support
  • Contact us
  • House rules
  • Privacy Policy
  • Terms of use
  • Competition terms & conditions
  • Our use of AI
Subscriber Services
  • Whanganui Chronicle e-edition
  • Manage your print subscription
  • Manage your digital subscription
  • Subscribe to Herald Premium
  • Subscribe to the Whanganui Chronicle
  • Gift a subscription
  • Subscriber FAQs
  • Subscription terms & conditions
  • Promotions and subscriber benefits
NZME Network
  • Whanganui Chronicle
  • The New Zealand Herald
  • The Northland Age
  • The Northern Advocate
  • Waikato Herald
  • Bay of Plenty Times
  • Rotorua Daily Post
  • Hawke's Bay Today
  • Viva
  • NZ Listener
  • Newstalk ZB
  • BusinessDesk
  • OneRoof
  • Driven Car Guide
  • iHeart Radio
  • Restaurant Hub
NZME
  • NZME Events
  • About NZME
  • NZME careers
  • Advertise with NZME
  • Digital self-service advertising
  • Book your classified ad
  • Photo sales
  • © Copyright 2025 NZME Publishing Limited
TOP